Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.
Mark T RedingMindy SimpsonJonathan DucorePål Andrè HolmeMonika Maas EnriquezMaria Elisa Mancuso
Published in: Acta haematologica (2024)
Efficacy and safety of damoctocog alfa pegol were confirmed in adolescent patients with haemophilia A, with data for up to 6 years supporting its use as a long-term treatment option in this group as they transition into adulthood.